Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.
The results of the collaborative research, published today in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as age-related macular degeneration (AMD).
AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an ageing population.
A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.
This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.
Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.
The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.
Dr de Cogan said: “The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.
“Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments.
“The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.
“We believe this is going to be very important in terms of empowering of patients and reducing the cost of treatment to the NHS.”
The Latest on: Age-related macular degeneration
Ophthalmology Pipeline Database 2018: Conjunctivitis, Glaucoma, Diabetic Retinopathy, Myasthenia Gravis, Dry Eye Syndrome, Age-related Macular Degeneration, and Cataract ...
on April 18, 2018 at 10:11 am
DUBLIN--(BUSINESS WIRE)--The "Ophthalmology Pipeline Database - 2018" report has been added to ResearchAndMarkets.com's offering. Ophthalmology Pipeline Highlights Database - 2018, provides most up-to-date information on key pipeline products in the global ... […]
Tiny, light-sensitive chips developed by Stanford researchers could one day restore sight to the blind
on April 18, 2018 at 1:24 am
Age-related macular degeneration, a disease that slowly degrades light-sensitive cells in the retina, is the leading cause of vision loss and blindness among people 65 and older, according to the Centers for Disease Control and Prevention. Doctors can’t ... […]
Ask the Expert: Macular degeneration can lead to difficulty reading, recognizing faces and performing other fine tasks
on April 17, 2018 at 3:41 am
What is macular degeneration? Age-related macular degeneration is the leading cause of severe visual loss in the population over the age of 65. The disease causes weakening of the macula, which is the small area at the center of the retina, which is ... […]
Are you at risk for macular degeneration?
on April 13, 2018 at 6:51 am
Many people accept deteriorating eyesight as an inevitable part of getting older, but blurry or distorted vision – such as when straight lines appear wavy – could be signs of age-related macular degeneration. The condition is the most common cause of ... […]
New Retinal Implant Produces Hope of Cure for Macular Degeneration
on April 12, 2018 at 2:00 pm
Actually, you may not. At least, not if you’re one of the 11 million people in the United States who have some form of age-related macular degeneration. That’s 22 million eyes that don’t function properly anymore. For most of these eyes, there’s no ... […]
via Google News and Bing News